These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25222143)

  • 1. Small-molecule control of cytokine function: new opportunities for treating immune disorders.
    Sundberg TB; Xavier RJ; Schreiber SL; Shamji AF
    Curr Opin Chem Biol; 2014 Dec; 23():23-30. PubMed ID: 25222143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule approaches to treat autoimmune and inflammatory diseases (Part III): Targeting cytokines and cytokine receptor complexes.
    Zheng J; Chen D; Xu J; Ding X; Wu Y; Shen HC; Tan X
    Bioorg Med Chem Lett; 2021 Sep; 48():128229. PubMed ID: 34214508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.
    Xu P; Shen P; Yu B; Xu X; Ge R; Cheng X; Chen Q; Bian J; Li Z; Wang J
    Eur J Med Chem; 2020 Apr; 192():112155. PubMed ID: 32120325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.
    Gadina M; Gazaniga N; Vian L; Furumoto Y
    J Autoimmun; 2017 Dec; 85():20-31. PubMed ID: 28676205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting RORγt/Th17 axis for autoimmune disorders.
    Isono F; Fujita-Sato S; Ito S
    Drug Discov Today; 2014 Aug; 19(8):1205-11. PubMed ID: 24792721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of potent small molecule activators of human STING.
    Pryde DC; Middya S; Banerjee M; Shrivastava R; Basu S; Ghosh R; Yadav DB; Surya A
    Eur J Med Chem; 2021 Jan; 209():112869. PubMed ID: 33038794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulating Drugs Based on Poxviral Proteins.
    Shchelkunova GA; Shchelkunov SN
    BioDrugs; 2016 Feb; 30(1):9-16. PubMed ID: 26820996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK-STAT inhibitors for the treatment of immunomediated diseases.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Th17 cells in autoimmune diseases.
    Yang J; Sundrud MS; Skepner J; Yamagata T
    Trends Pharmacol Sci; 2014 Oct; 35(10):493-500. PubMed ID: 25131183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases.
    Damsky W; Peterson D; Ramseier J; Al-Bawardy B; Chun H; Proctor D; Strand V; Flavell RA; King B
    J Allergy Clin Immunol; 2021 Mar; 147(3):814-826. PubMed ID: 33129886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors.
    Zheng J; Wu J; Ding X; Shen HC; Zou G
    Bioorg Med Chem Lett; 2021 Apr; 38():127862. PubMed ID: 33609659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors.
    Wang X; Liu Y; Han X; Zou G; Zhu W; Shen H; Liu H
    Bioorg Med Chem Lett; 2021 Jul; 44():128101. PubMed ID: 33984476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytokines].
    Feuchtenberger M; Kneitz C; Tony HP
    Z Rheumatol; 2007 Jul; 66(4):297-8, 300-3. PubMed ID: 17522870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.
    Chen S; Song Z; Zhang A
    Curr Top Med Chem; 2019; 19(3):180-185. PubMed ID: 30854972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
    Xie Z; Yang X; Duan Y; Han J; Liao C
    J Med Chem; 2021 Feb; 64(3):1283-1345. PubMed ID: 33481605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and approaches for the development of safer immunomodulatory biologics.
    Sathish JG; Sethu S; Bielsky MC; de Haan L; French NS; Govindappa K; Green J; Griffiths CE; Holgate S; Jones D; Kimber I; Moggs J; Naisbitt DJ; Pirmohamed M; Reichmann G; Sims J; Subramanyam M; Todd MD; Van Der Laan JW; Weaver RJ; Park BK
    Nat Rev Drug Discov; 2013 Apr; 12(4):306-24. PubMed ID: 23535934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modern anti-cytokine therapy of autoimmune diseases.
    Astrakhantseva IV; Efimov GA; Drutskaya MS; Kruglov AA; Nedospasov SA
    Biochemistry (Mosc); 2014 Dec; 79(12):1308-21. PubMed ID: 25716724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cytokine deficiencies and cytokine autoantibodies in clinical dermatology.
    Liszewski W; Gniadecki R
    J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):404-12. PubMed ID: 26372900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expanding role of immunopharmacology: IUPHAR Review 16.
    Tiligada E; Ishii M; Riccardi C; Spedding M; Simon HU; Teixeira MM; Cuervo ML; Holgate ST; Levi-Schaffer F
    Br J Pharmacol; 2015 Sep; 172(17):4217-27. PubMed ID: 26173913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
    Foster JG; Blunt MD; Carter E; Ward SG
    Pharmacol Rev; 2012 Oct; 64(4):1027-54. PubMed ID: 23023033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.